---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-160146"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2024-06-13T23:59:59+00:00"
generated_at: "2026-06-01T04:36:33.255211+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO appoints COO Curran Simpson as CEO; founder Kenneth Mills becomes Chairman

## Summary
- Curran Simpson, former COO, appointed President and CEO effective July 1, 2024; also named to Board.
- Co-founder Kenneth Mills steps down as CEO, becomes Chairman of the Board; advisor until June 2025.
- Simpson's compensation: base salary $610k, bonus target 60%, equity grant $2.5M (75% options, 25% RSUs).
- Daniel Tassé appointed Lead Independent Director, replacing Jerry Karabelas.
- Company reiterates cash guidance: $380.5M as of March 31, 2024, funding ops into 2026.

## SEC filing metadata
- accession: 0001193125-24-160146
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2024-06-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000119312524160146/0001193125-24-160146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000119312524160146/d718851d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-160146
- JSON: https://secwatch.observer/filing/0001193125-24-160146.json
- Plain text: https://secwatch.observer/filing/0001193125-24-160146.txt

## Key facts
- Executive change
  Daniel Tassé was appointed as Lead Independent Director at REGENXBIO Inc..
  - Action: appointed
  - Role: Lead Independent Director
  source text: Daniel Tassé was appointed as the Company's Lead Independent Director, succeeding Jerry Karabelas.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590877/000119312524160146/0001193125-24-160146-index.htm
- Executive change
  Curran M. Simpson was appointed as President and Chief Executive Officer at REGENXBIO Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: the Company also announced that the Board appointed Curran M. Simpson as President and Chief Executive Officer, effective as of July 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590877/000119312524160146/0001193125-24-160146-index.htm
- Executive change
  Curran M. Simpson was appointed as Class I director at REGENXBIO Inc..
  - Action: appointed
  - Role: Class I director
  source text: In connection with his appointment, the Board appointed Mr. Simpson as a Class I director, effective July 1, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590877/000119312524160146/0001193125-24-160146-index.htm
- Executive change
  Jerry Karabelas departed as Lead Independent Director at REGENXBIO Inc..
  - Action: succeeded
  - Role: Lead Independent Director
  source text: Daniel Tassé was appointed as the Company's Lead Independent Director, succeeding Jerry Karabelas.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590877/000119312524160146/0001193125-24-160146-index.htm
- Executive change
  Kenneth T. Mills was appointed as Chairman of the Board at REGENXBIO Inc..
  - Action: appointed
  - Role: Chairman of the Board
  source text: accepted the resignation of Kenneth T. Mills from his position as President and Chief Executive Officer of the Company, effective July 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590877/000119312524160146/0001193125-24-160146-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.